# A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors

> **NCT07208773** · PHASE1,PHASE2 · RECRUITING · sponsor: **MediLink Therapeutics (Suzhou) Co., Ltd.** · enrollment: 260 (estimated)

## Conditions studied

- Advanced Solid Tumors
- Non Small Cell Lung Cancer
- Small Cell Lung Cancer

## Interventions

- **DRUG:** YL201
- **DRUG:** Ivonescimab

## Key facts

- **NCT ID:** NCT07208773
- **Lead sponsor:** MediLink Therapeutics (Suzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-29
- **Primary completion:** 2027-01
- **Final completion:** 2027-12
- **Target enrollment:** 260 (ESTIMATED)
- **Last updated:** 2025-11-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07208773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07208773, "A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07208773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*